Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences other Products (Cayston, Jyseleca, Letairis, Zydelig) ($M) ($M)
Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary
Latest, Q2 2026
51
Period ended Jun 30, 2026
Change on a year earlier
-30.1%
73 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
30
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up other products (cayston, jyseleca, letairis, zydelig) ($m)
- Other Products (Cayston, Jyseleca, Letairis, Zydelig) — U.S. sales ($M)22 · Q2 2026
- Other Products (Cayston, Jyseleca, Letairis, Zydelig) — Europe sales ($M)8 · Q2 2026
- Other Products (Cayston, Jyseleca, Letairis, Zydelig) — Rest of World sales ($M)21 · Q2 2026
- Other Products (Cayston, Jyseleca, Letairis, Zydelig) — Worldwide YoY growth (%)-20.0% · Q2 2026
Cite this data
StockData. (2026). Gilead Sciences Other Products (Cayston, Jyseleca, Letairis, Zydelig) ($M) ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/other_misc
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.